One Hundred and twentY-FIRST issue
october 28th, 2026
Evaluating the performance of melanoma risk prediction models
JAMA Dermatology
JAMA Dermatology
Melanomas will find a way to defeat the odds.
Melanoma risk prediction models may help identify high-risk individuals for targeted screening and prevention. However, their accuracy remains uncertain and external validation is essential to determine how reliably available models predict melanoma risk. In this population-based cohort study, investigators evaluated 6 published melanoma risk prediction models using data from up to 43,235 Australian adults aged 45 years and older, comparing predicted 10-year melanoma risk with actual diagnoses identified through cancer registry records.
What did they find?
Main Takeaway: Melanoma risk prediction models may help guide more personalized screening and prevention strategies. However, improving their reliability across diverse populations will be essential before routine clinical implementation.
Melanoma risk prediction models may help identify high-risk individuals for targeted screening and prevention. However, their accuracy remains uncertain and external validation is essential to determine how reliably available models predict melanoma risk. In this population-based cohort study, investigators evaluated 6 published melanoma risk prediction models using data from up to 43,235 Australian adults aged 45 years and older, comparing predicted 10-year melanoma risk with actual diagnoses identified through cancer registry records.
What did they find?
- Model accuracy varied, with AUC values ranging from 0.58 to 0.70.
- The Vuong and Olsen (invasive and in situ) models, which incorporated factors such as skin pigmentation, mole count, and personal or family history of skin cancer, performed best (AUC = 0.70).
- The Whiteman and Olsen (invasive) models performed similarly (AUC = 0.69), followed by the Cho model (AUC = 0.66).
- The Quéreux model performed worst (AUC = 0.58). It used a different combination of risk factors, including skin type, freckles, mole count, and number of childhood sunburns.
- While several models showed promise for identifying individuals at higher melanoma risk, most underestimated the likelihood of developing melanoma, highlighting the need for further refinement before widespread clinical use.
Main Takeaway: Melanoma risk prediction models may help guide more personalized screening and prevention strategies. However, improving their reliability across diverse populations will be essential before routine clinical implementation.
Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of phase 3 randomized, placebo-controlled clinical trial and an open-label extension study
JAAD
JAAD
When your eczema medication has you reaching new heights.
Children with moderate-to-severe atopic dermatitis (AD) may experience impaired linear growth and reduced bone mineral density, potentially related to chronic inflammation, sleep disruption, and corticosteroid exposure. Whether effective systemic treatment can improve these outcomes remains unclear. In this post hoc analysis, investigators evaluated 304 children aged 6-11 years with severe AD who received either dupilumab or placebo for 16 weeks. All children then received dupilumab through week 52, with investigators assessing changes in height and bone biomarkers over time.
What did they find?
Main Takeaway: Dupilumab treatment was associated with improved linear growth and increased bone formation biomarkers in children with severe AD, particularly those initially in lower height percentiles. These findings suggest that effective control of AD may provide benefits beyond skin clearance, potentially supporting healthy skeletal development during childhood.
Children with moderate-to-severe atopic dermatitis (AD) may experience impaired linear growth and reduced bone mineral density, potentially related to chronic inflammation, sleep disruption, and corticosteroid exposure. Whether effective systemic treatment can improve these outcomes remains unclear. In this post hoc analysis, investigators evaluated 304 children aged 6-11 years with severe AD who received either dupilumab or placebo for 16 weeks. All children then received dupilumab through week 52, with investigators assessing changes in height and bone biomarkers over time.
What did they find?
- Children with severe AD were overrepresented in lower height percentiles at baseline, with bone alkaline phosphatase (BALP) levels near the lower end of normal.
- Among children below the 40th height percentile, 31.3% receiving dupilumab achieved a ≥5-percentile height increase at week 16 versus 15.5% with placebo (OR = 2.5, 95% CI = 1.1-5.8, p = 0.0357).
- Height improvements continued through week 52, with 50.7% of continuously treated children initially below the 40th percentile achieving a ≥5-percentile increase.
- BALP levels increased significantly with dupilumab versus placebo at week 16 (77.3-81.8 vs 65.0 µg/L), with further increases through week 52 (78.6-82.1 µg/L) and comparable levels in children who switched from placebo to dupilumab (82.1 µg/L).
Main Takeaway: Dupilumab treatment was associated with improved linear growth and increased bone formation biomarkers in children with severe AD, particularly those initially in lower height percentiles. These findings suggest that effective control of AD may provide benefits beyond skin clearance, potentially supporting healthy skeletal development during childhood.
Breaking out of the algorithm might be the first step in treating early acne.
Acne affects over 90% of young people, and early effective treatment reduces the risk of scarring and psychosocial harm. However, little remains known about how young people find acne information and products or how parents shape their care. As part of the Acne Care Online research program, this qualitative study conducted semistructured interviews with 21 young people aged 13–25 years, 5 parents, and 3 parent-child pairs recruited via social media across England.
What did they find?
Main Takeaway: Despite distrust, young people with acne rely heavily on social media to choose treatments, while parents control access to clinicians. Evidence-based acne resources should target both groups and clinicians should actively point patients toward them.
Acne affects over 90% of young people, and early effective treatment reduces the risk of scarring and psychosocial harm. However, little remains known about how young people find acne information and products or how parents shape their care. As part of the Acne Care Online research program, this qualitative study conducted semistructured interviews with 21 young people aged 13–25 years, 5 parents, and 3 parent-child pairs recruited via social media across England.
What did they find?
- Social media (YouTube, TikTok, Instagram) was a main source for finding acne products among young people but not parents, and participants valued its accessibility and video format over sources like the NHS website despite knowing it could be unreliable.
- Young people judged trustworthiness by shared experience and familiarity, cross-checking reviews and comment-section consensus, favoring advice from people with similar skin, and preferring recognizable high-street brands.
- Parents often acted as gatekeepers to professional care, arranging and attending appointments, though some delayed consulting due to reluctance about medication, assumed prescriptions meant “pills,” and preferred natural remedies or lifestyle changes.
- Both young people and parents lacked awareness of evidence-based treatments such as pharmacy-available topicals, and few had ever consulted a clinician for their acne (22% of those aged 13–15 and 53% of those aged 16–24).
Main Takeaway: Despite distrust, young people with acne rely heavily on social media to choose treatments, while parents control access to clinicians. Evidence-based acne resources should target both groups and clinicians should actively point patients toward them.
Do RDEB fibroblasts get lazier as the disease progresses?
Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic blistering disorder caused by collagen VII deficiency, in which repeated skin injury drives progressive, disfiguring fibrosis. Although fibroblasts are the principal effector cells of RDEB fibrosis, the phenotypic and molecular changes they undergo during disease progression have remained poorly defined. The investigators compared dermal fibroblasts from early- and advanced-stage RDEB donors, used signaling inhibitors to identify drivers of fibroblast behavior, and validated key findings in patient skin and an RDEB mouse model.
What did they find?
Main Takeaway: As RDEB progresses, dermal fibroblasts shift from a contractile, EGFR- and AKT-driven phenotype to a less contractile but pro-fibrotic, matrix-producing phenotype. This stage-dependent switch helps explain how RDEB fibrosis evolves and suggests that the best antifibrotic approach may differ between early and advanced disease.
Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic blistering disorder caused by collagen VII deficiency, in which repeated skin injury drives progressive, disfiguring fibrosis. Although fibroblasts are the principal effector cells of RDEB fibrosis, the phenotypic and molecular changes they undergo during disease progression have remained poorly defined. The investigators compared dermal fibroblasts from early- and advanced-stage RDEB donors, used signaling inhibitors to identify drivers of fibroblast behavior, and validated key findings in patient skin and an RDEB mouse model.
What did they find?
- RDEB fibroblasts from advanced disease had less of the contractility marker αSMA (p < 0.0001), more of the pro-fibrotic matrix protein tenascin-C (p = 0.0002), and weaker contraction of collagen gels (p = 0.0045) than those from early disease, revealing a shift from tissue contraction to scar-promoting matrix production as fibrosis progresses.
- Fibroblasts from advanced disease showed blunted EGFR activation (p = 0.0012), and of EGFR’s two main downstream pathways, only AKT activation was reduced (p = 0.0001) while ERK activation was unchanged.
- EGF stimulation of advanced-stage fibroblasts increased αSMA (p = 0.0036) and reduced tenascin-C (p = 0.0101), whereas EGFR inhibition reduced αSMA and increased tenascin-C in both early-stage (p = 0.0014, p = 0.0104) and advanced-stage fibroblasts (p = 0.0003, p = 0.0084), showing that EGFR activity drives the phenotypic change.
- Blocking AKT made fibroblasts less contractile, lowering αSMA (p = 0.0219) and raising the scar-promoting tenascin-C (p = 0.0331) in early-stage cells, while blocking ERK boosted αSMA and contraction (p = 0.0031).
Main Takeaway: As RDEB progresses, dermal fibroblasts shift from a contractile, EGFR- and AKT-driven phenotype to a less contractile but pro-fibrotic, matrix-producing phenotype. This stage-dependent switch helps explain how RDEB fibrosis evolves and suggests that the best antifibrotic approach may differ between early and advanced disease.
Looking for eschars? Hit them with that flex!
Scrub typhus (ST) is caused by the bacterium Orientia tsutsugamushi, which is transmitted by the Trombiculidae family of mites. When infection occurs, ST typically manifests cutaneously as the formation of eschars, and without treatment, the disease prognosis is often poor. In early ST, diagnosis relies upon identification of the eschars, which are categorized as typical eschars (TEs) and atypical eschars (ATEs) and differ in morphology, anatomical site, and the presence of regional lymphadenopathy. This single-center prospective observational study examined these disease characteristics among pediatric patients in South India with serology-positive ST.
What did they find?
Main Takeaway: Prompt identification of ATEs via morphology, anatomic distribution, and lack of associated regional lymphadenopathy supports ST diagnosis and clinical outcomes. Through accurate recognition of both TEs and ATEs, patients can receive timely intervention, improving disease morbidity and mortality.
Scrub typhus (ST) is caused by the bacterium Orientia tsutsugamushi, which is transmitted by the Trombiculidae family of mites. When infection occurs, ST typically manifests cutaneously as the formation of eschars, and without treatment, the disease prognosis is often poor. In early ST, diagnosis relies upon identification of the eschars, which are categorized as typical eschars (TEs) and atypical eschars (ATEs) and differ in morphology, anatomical site, and the presence of regional lymphadenopathy. This single-center prospective observational study examined these disease characteristics among pediatric patients in South India with serology-positive ST.
What did they find?
- Among 692 patients diagnosed with ST, 349 had eschars and did not receive treatment at other centers and were therefore included in analyses, with a mean age of 6.3 ± 3.3 years.
- The TE group consisted of 261 patients (74.8%) and 277 lesions, and the ATE group included 88 patients (25.2%) with 121 lesions, totalling 398 identified eschars, and the patient groups had similar ST severity and outcomes.
- Anatomically, TEs were most frequently found in flexural sites, whereas ATEs were typically identified in non-flexural locations.
- Variables that were inversely associated with ATEs included the presence of flexural eschars [adjusted odds ratio (aOR) = 0.310, 95% CI = 0.16 - 0.570, p < 0.001] and associated regional lymphadenopathy (aOR = 0.420, 95% CI = 0.230 - 0.780, p = 0.006), while predictors included having multiple eschars (aOR = 2.770, 95% CI = 1.163 - 6.75, p = 0.025) and leukocytosis (aOR = 2.220, 95% CI = 1.21 - 4.06, p = 0.011).
Main Takeaway: Prompt identification of ATEs via morphology, anatomic distribution, and lack of associated regional lymphadenopathy supports ST diagnosis and clinical outcomes. Through accurate recognition of both TEs and ATEs, patients can receive timely intervention, improving disease morbidity and mortality.
Ear me out!
Rosacea is a chronic inflammatory skin condition characterized by facial erythema, flushing, and burning. Previous research suggests that stimulation of the auricular branch of the vagus nerve may reduce inflammation, but the need for specialized devices has limited its accessibility. Researchers conducted a single-center, sham-controlled randomized clinical trial involving 204 patients with rosacea to evaluate whether device-free auricular acupressure could improve clinical symptoms and inflammatory biomarkers when added to standard treatment.
What did they find?
Main Takeaway: Device-free auricular acupressure may offer a low-cost, accessible adjunctive treatment for rosacea, improving overall disease severity while providing rapid relief of vascular symptoms. These findings also support further investigation into vagus nerve modulation as a nonpharmacologic approach to inflammatory skin diseases.
Rosacea is a chronic inflammatory skin condition characterized by facial erythema, flushing, and burning. Previous research suggests that stimulation of the auricular branch of the vagus nerve may reduce inflammation, but the need for specialized devices has limited its accessibility. Researchers conducted a single-center, sham-controlled randomized clinical trial involving 204 patients with rosacea to evaluate whether device-free auricular acupressure could improve clinical symptoms and inflammatory biomarkers when added to standard treatment.
What did they find?
- Greater treatment success: At 8 weeks, 56.9% of patients receiving active auricular acupressure achieved Investigator Global Assessment (IGA) treatment success compared with 35.3% in the sham group (RR = 1.61, 95% CI = 1.18–2.20, p = 0.003; NNT = 5).
- Rapid improvement in vascular symptoms: Immediate vascular improvement occurred in 59.3% of the active treatment group compared with only 7.4% of the sham group (p < 0.001).
- Reduced inflammatory biomarkers: Active acupressure resulted in significant reductions in serum LL-37, CGRP, TNF-α, and IL-6, supporting a potential neuroimmune mechanism.
- Sustained benefits and safety: At 20 weeks, the active treatment group maintained significantly lower IGA and Clinical Erythema Assessment scores, with no serious adverse events reported.
Main Takeaway: Device-free auricular acupressure may offer a low-cost, accessible adjunctive treatment for rosacea, improving overall disease severity while providing rapid relief of vascular symptoms. These findings also support further investigation into vagus nerve modulation as a nonpharmacologic approach to inflammatory skin diseases.
Effectiveness and safety of a moisturizer containing Centella asiatica extract, ceramide NP, and panthenol for erythema and skin barrier in erythematotelangiectatic rosacea: a randomized controlled trial study
Integrative Dermatology
Integrative Dermatology
Red is dead.
Persistent redness can make rosacea difficult to manage, and supportive skincare is an important part of treatment. This study tested a moisturizer combining Centella asiatica (“cica”) extract , ceramide NP, and panthenol. In a 28-day randomized, single-blind trial, 80 adults in China received either the investigational moisturizer or Cetaphil daily hydrating lotion twice daily, alongside oral minocycline 50 mg daily.
What did they find?
Main Takeaway: The cica, ceramide NP, and panthenol moisturizer improved redness, hydration, and quality of life during minocycline treatment. The findings support the tested formulation as adjunctive skincare, while leaving cica’s independent contribution uncertain.
Persistent redness can make rosacea difficult to manage, and supportive skincare is an important part of treatment. This study tested a moisturizer combining Centella asiatica (“cica”) extract , ceramide NP, and panthenol. In a 28-day randomized, single-blind trial, 80 adults in China received either the investigational moisturizer or Cetaphil daily hydrating lotion twice daily, alongside oral minocycline 50 mg daily.
What did they find?
- Redness improved more with the cica-containing cream. Median reductions in the imaging-based redness measure were 4.90 versus 1.09 arbitrary units (p < 0.001), and reductions in facial red area were 0.22 versus 0.09 arbitrary units (p = 0.025).
- Skin hydration increased more, but water loss did not differ significantly between groups. Median hydration gains were 17.00 versus 8.00 units (p < 0.001); between-group differences in transepidermal water loss were not significant.
- Rosacea-related quality of life improved. Median reductions in RosQol scores were 16.00 versus 5.30 points by day 28 (p < 0.001).
- Five participants discontinued because of possibly product-related adverse events. These occurred in 1/40 participants using the experimental cream and 4/40 using the control lotion; all resolved after the products were stopped.
Main Takeaway: The cica, ceramide NP, and panthenol moisturizer improved redness, hydration, and quality of life during minocycline treatment. The findings support the tested formulation as adjunctive skincare, while leaving cica’s independent contribution uncertain.
The planet is getting hotter, pathogens are getting stronger, and your skin is what takes the heat.
Climate change acts as a “threat multiplier” in global disparities, disproportionately burdening populations already facing socioeconomic, political, and structural disadvantages. Because the skin directly interfaces with external stressors, environmental instability contributes to an increased incidence and severity of skin diseases. This review examines these ecological impacts on dermatologic disease burden, access to care, and global health equity.
What did they find?
Main Takeaway: Advocating for skin and planetary health requires action at every level of clinical practice and policy. Dermatologists can counsel patients on environmental skin risks, partner with health systems to drive sustainability and waste reduction in dermatologic product packaging, and advocate globally for climate justice and equitable resource access.
Climate change acts as a “threat multiplier” in global disparities, disproportionately burdening populations already facing socioeconomic, political, and structural disadvantages. Because the skin directly interfaces with external stressors, environmental instability contributes to an increased incidence and severity of skin diseases. This review examines these ecological impacts on dermatologic disease burden, access to care, and global health equity.
What did they find?
- Flooding, rising sea levels, higher temperatures, and humidity lead to pathogens developing thermotolerance and enhanced virulence, promoting infectious diseases including Mycobacterium marinum, Aeromonas, Vibrio, Leptospirosis, Candida, and Malassezia.
- Extended pollen seasons due to global warming increase aeroallergens, and air pollution from fossil fuel combustion induces oxidative stress, activates genotoxic pathways, and triggers inflammatory cytokine production, which worsens inflammatory skin diseases like atopic dermatitis and psoriasis.
- Driven by rising global levels and amplified by workplace heat and pollution, ultraviolet radiation exposure affects 1.6 billion individuals worldwide and causes nearly one-third of all global non-melanoma skin cancer deaths, while accelerating overall rates of melanoma, dyspigmentation, and premature skin aging.
- Low- and middle-income countries disproportionately bear climate-related dermatologic morbidity. Africa, the Middle East, South Asia, and Latin America experience intensified climate exposure and an increased dermatologic burden, but often lack the specialists, healthcare infrastructure, and access to essential care.
Main Takeaway: Advocating for skin and planetary health requires action at every level of clinical practice and policy. Dermatologists can counsel patients on environmental skin risks, partner with health systems to drive sustainability and waste reduction in dermatologic product packaging, and advocate globally for climate justice and equitable resource access.